Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 17/20 | 1.00 |
| ▸ | TACR1 | P25103 | 16/20 | 1.00 |
| ▸ | TACR3 | P29371 | 9/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | CCR5 | P51681 | 2/20 | 0.65 |
| ▸ | HRH1 | P35367 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Osanetant SCHEMBL119440 | 1.00 | TACR2 (1.00) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| Osanetant SCHEMBL30961738 | 1.00 | TACR2 (1.00) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| Osanetant SCHEMBL4080131 | 1.00 | TACR2 (1.00) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| Osanetant SCHEMBL29371450 | 1.00 | TACR2 (1.00) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| Osanetant SCHEMBL5679471 | 0.99 | TACR2 (0.98) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| Osanetant SCHEMBL6543149 | 0.99 | TACR2 (0.98) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| SCHEMBL8136920 | 0.97 | TACR2 (0.95) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL6543864 | 0.97 | TACR2 (0.94) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| SCHEMBL24855515 | 0.96 | TACR2 (0.92) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| SCHEMBL31224281 | 0.96 | TACR2 (0.92) | TACR2TACR1TACR3CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240336565-A1 | SOLID FORMS OF OSANETANT | ACER THERAPEUTICS INC. | 2024-10-10 | — | — | US | claimed |
| EP-3915560-A1 | METHODS OF MANAGING CONDITIONED FEAR WITH NEUROKININ RECEPTOR ANTAGONISTS | Emory University (US) | 2021-12-01 | — | — | EP | claimed |
| EP-3160469-B1 | METHODS OF MANAGING CONDITIONED FEAR WITH NEUROKININ RECEPTOR ANTAGONISTS | UNIV EMORY (US) | 2021-04-28 | — | — | EP | claimed |
| US-10314835-B2 | Methods of managing conditioned fear with neurokinin receptor antagonists | EMORY UNIVERSITY (US) | 2019-06-11 | — | — | US | claimed |
| US-10052317-B2 | Method for treating or preventing hot flushes | IMPERIAL INNOVATIONS LIMITED (GB) | 2018-08-21 | — | — | US | claimed |
| US-20170296528-A1 | Methods of Managing Conditioned Fear with Neurokinin Receptor Antagonists | ACER THERAPEUTICS INC. | 2017-10-19 | — | — | US | claimed |
| EP-3169700-A1 | ANTAGONISTS OF NEUROKININ B IN FISH REPRODUCTION | Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. (IL) | 2017-05-24 | — | — | EP | claimed |
| EP-3160469-A2 | METHODS OF MANAGING CONDITIONED FEAR WITH NEUROKININ RECEPTOR ANTAGONISTS | Emory University (US) | 2017-05-03 | — | — | EP | claimed |
| WO-2016009439-A1 | ANTAGONISTS OF NEUROKININ B IN FISH REPRODUCTION | YISSUME RESEARCH DEVELOMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2016-01-21 | — | — | WO | claimed |
| WO-2015200594-A2 | METHODS OF MANAGING CONDITIONED FEAR WITH NEUROKININ RECEPTOR ANTAGONISTS | EMORY UNIVERSITY (US) | 2015-12-30 | — | — | WO | claimed |
| EP-0858325-B1 | STABLE FREEZE-DRIED PHARMACEUTICAL FORMULATION | SANOFI SYNTHELABO (FR) | 2002-07-31 | — | — | EP | claimed |
| US-6294537-B1 | NEUROKININS USED FOR TREATMENT OF DISEASES | SANOFI-SYNTHELABO (FR) | 2001-09-25 | — | — | US | claimed |
| EP-0673928-B1 | Novel N-(3,4-dichlorophenyl-propyl)-piperidine derivatives as selective human NK3-receptor antagonists | SANOFI SYNTHELABO (FR) | 2001-08-29 | — | — | EP | claimed |
| US-6124316-A | ACTIVE DRUG TREATING PSYCHIATRIC DISEASES, DISEASES OF PSYCHOSOMATIC ORIGIN, OF HYPERTENSION AND, NERVOUS SYSTEM DISORDERS | SANOFI (FR) | 2000-09-26 | — | — | US | claimed |
| EP-0673928-A1 | Novel N-(3,4-dichlorophenyl-propyl)-piperidine derivatives as selective human NK3-receptor antagonists | SANOFI (FR) | 1995-09-27 | — | — | EP | claimed |
| JP-8048669-A | — | — | None | — | — | JP | disclosed |
| US-20240336565-A1 | SOLID FORMS OF OSANETANT | ACER THERAPEUTICS INC. | 2024-10-10 | — | — | US | disclosed |
| WO-1997010211-A1 | NOVEL HUMAN NK3 RECEPTOR-SELECTIVE ANTAGONIST COMPOUNDS, METHOD FOR OBTAINING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI (FR) | 1997-03-20 | — | — | WO | disclosed |
| JP-H0848669-A | COMPOUND WHICH IS SELECTIVE ANTAGONIST OF HUMAN NK3 RECEPTOR AND USE THEREOF AS MEDICINAL PRODUCT AND DIAGNOSTIC TOOL | SANOFI SA | 1996-02-20 | — | — | JP | disclosed |
| EP-0673928-A1 | Novel N-(3,4-dichlorophenyl-propyl)-piperidine derivatives as selective human NK3-receptor antagonists | SANOFI (FR) | 1995-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170296528-A1 | Methods of Managing Conditioned Fear with Neurokinin Receptor Antagonists | PNMT, TACR2, HTR3C | TACR2 2/4885TACR1 6/4885TACR3 31/4885 |
| US-20240336565-A1 | SOLID FORMS OF OSANETANT | OAT, OPA1, CPS1 | TACR2 1620/4885TACR1 898/4885TACR3 2174/4885 |
| US-10052317-B2 | Method for treating or preventing hot flushes | KLK5, KISS1R, KLKB1 | TACR2 10/4885TACR1 11/4885TACR3 7/4885 |
| US-10314835-B2 | Methods of managing conditioned fear with neurokinin receptor antagonists | PNMT, TACR2, HTR3C | TACR2 2/4885TACR1 6/4885TACR3 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.